Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline ...
Regeneron loses key defense in COVID-19 treatment patent lawsuit Legalcategory· October 4, 2024 The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback